Navigation Links
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
Date:5/15/2009

er expanded its clinical development efforts for ENMD-2076 and has commenced a Phase 1 study in patients with relapsed or refractory leukemia. The study will be conducted at the Princess Margaret Hospital in Toronto, Ontario and Karen Yee, M.D., will serve as Principal Investigator. Although the primary endpoints of the study include defining the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ENMD-2076 administered orally in patients with relapsed or refractory leukemia, the study will also evaluate pharmacodynamic effects of ENMD-2076 by collaborating with Dr. David Hedley, Department of Molecular Oncology, Ontario Cancer Institute (OCI).

Dr. Mark R. Bray, EntreMed Vice President, Research commented, "We are very excited to be working with Dr. Hedley and his staff, who have considerable experience in evaluating the mechanistic effects of kinase inhibitors like ENMD-2076 in cancer patients. The close proximity of EntreMed scientific personnel based in Toronto to our clinical collaborators at the OCI will facilitate our ability to obtain the maximum value from this study and its correlative components."

In addition, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for ENMD-2076 for the treatment of ovarian cancer. Several ovarian cancer patients participated in the ENMD-2076 Phase 1 study in solid tumors and will be included in the data presentations at ASCO. Orphan drug is a designation by the Food and Drug Administration indicating a therapy developed to treat diseases that affect fewer than 200,000 persons in the United States. Sponsors of drugs granted orphan designation qualify for tax credit and marketing exclusivity incentives of the Orphan Drug Act. Previously EntreMed had received orphan drug designation for ENMD-2076 for multiple myeloma.

EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., commented, "The clinical development
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
2. EntreMed to Present at the New York Society of Security Analysts Industry Conference
3. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
4. EntreMed Reports Third Quarter 2008 Financial Results
5. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
6. EntreMed to Present at BioPartnering Europe Conference
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. EntreMed Reports Second Quarter 2008 Financial Results
9. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
10. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Biofertilizers stimulate microbial activities in ... and phosphorous through the activities in the soil or ... due to the stress on reducing environmental pollution and ... report defines and segments the bio fertilizers market with ...
(Date:1/22/2015)... COLUMBIA, Md. (PRWEB) January 22, 2015 ... of its new UV-1280 multipurpose UV-visible spectrophotometer. Offering ... compact, high-quality instrument is ideal for applications in ... and life science. , The user-friendly UV-1280 enables ...
(Date:1/22/2015)... (PRWEB) January 21, 2015 Cambridge Semantics, the ... technology, today announced that 2014 was a record-breaking year across ... capabilities of the Anzo Smart Data Platform and our Smart ... utilize insights from diverse data which led to record growth ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... The exodus continues at Merge Technologies, Inc. , ... Merge Healthcare, has announced that it received "a written notification ... co-CEO, and president of Merge subsidiary Cedara Software , ... Aug. 18. , ,Pedlar is the fifth executive to leave ...
... Wis. - Within a new ownership arrangement, an ... better positioned to expand production capabilities. , , Scientific ... components with annual sales of $60 million, has been ... Capital Strategies, Ltd. , Bethesda, Md. , ,American Capital's ...
... Madison, Wis. - Watching vacation highlights or memorable events ... the line between the nauseating and the soporific. , ,However, ... make the experience a little easier to swallow. With new ... a video of a birthday party could be made into ...
Cached Biology Technology:Pedlar the latest executive to leave Merge 2Protein lab could prosper under new owner 2
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced the ... Button Synaptics Fingerprint Sensor Technology Analysis" report to ... Based on a totally different sensing technology ... time a fingerprint sensor in its product. ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming the ... at international borders. Over the past decade, ePassports, biometric ... to self process through border control via eGates and ... of airports, seaports, and land borders across the globe. ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... NASA embarked on a revolutionary new mission for its ... space as an inter-related whole, rather than as individual ... symposium June 22-24 to examine the accomplishments of 20 ... what discoveries and opportunities lay ahead. Reporters ...
... PARK, Calif. May 13, 2009 SRI International, an ... that it will screen a library of well-characterized drugs ... as "swine flu." The work will be performed ... and Infectious Diseases (DMID) in the National Institute of ...
... take just hours after the symptoms appear for someone ... research, experts at The University of Nottingham have finally ... break through the body,s natural defence mechanism and attack ... better treatment and vaccines for meningitis and could save ...
Cached Biology News:SRI International to screen drugs that fight 2009 H1N1 influenza A 2Breakthrough in the treatment of bacterial meningitis 2
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
PPIF Antibody...
Biology Products: